Donald Trump’s 200% tariffs on pharma: Why India’s generic medicines could still remain competitive
Donald Trump announced up to 200% tariffs on generic drugs, with a two-year exemption until August 1, 2028.
Starting August 2028, generic imports face a 100% tariff for one year, then 200% from August 2029.
The policy aims to pressure manufacturers to shift production to the United States.
India’s pharmaceutical exports to the US were $9.7 billion, making it highly exposed to the tariffs.
Previously, tariffs were imposed on branded medicines and ingredients; generic medicines were brought into the regime on July 21.
Story angle
Center-right
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Times of India
Center-right
Mixed factuality
Who owns this?
Times Group
Bennett, Coleman & Co. (Sahu Jain family)
India's largest newspaper group by circulation.
Wikipedia: Sahu Jain family